别嘌呤醇（CAS 315-30-0）：分子式 C5H4N4O、分子量 136.11。
| CAS号 | 315-30-0 |
|---|---|
| 分子式 | C5H4N4O |
| 分子量 | 136.11 |
| 熔点 | >300 |
| 沸点 | 250.36 |
| LogP | -1.8 |
| 应用领域 | Uses: MEDICATION、MEDICATION (Vet):、THERAPEUTIC CATEGORY: Treatment of hyperuricemia and chronic gout、antiurolithic.、Use (kg) in Switzerland (2009): >5000、Use (kg、approx.) in Germany (2009): >100000、Use (kg) in USA (2002): 59900、Use (kg) in France (2004): 54247、Consumption (g per capita) in Switzerland (2009): 0.64、Consumption (g per capita、approx.) in Germany (2009): 1.2、Consumption (g per capita) in the USA (2002): 0.21、Consumption (g per capita) in France (2004): 0.9、Excretion rate: 0.28、Calculated removal (%): 75.1、For the treatment of hyperuricemia associated with primary or secondary gout. Also indicated for the treatment of primary or secondary uric acid nephropathy、with or without the symptoms of gout、as well as chemotherapy-induced hyperuricemia and recurrent renal calculi.、Methods of Manufacturing: Reaction of malononitrile and triethyl orthoformate to form ethoxymethylene malononitrile which is reacted with hydrazine、hydrolyzed、and condensed with formamide.、(Ethoxymethylene)malononitrile is reacted with hydrazine hydrate via deethanolation and addition thus cyclizing to form 3-aminopyrazole-4-carbonitrile. Controlled hydration of nitrile forms the corresponding carboxamide which、on condensation with formamide、yields allopurinol.、Formulations、Preparations: Allopurinol Preparations: (AHFS、2009)、Table: Allopurinol Preparations: (AHFS、2009) [Table#4346]、Oral Tablets、100 mg、Lopurin (scored)、Boots、Zyloprim (with povidone、scored)、Burroughs Wellcome、300 mg、Burroughs Wellcome.、Tablets、100 and 300 mg、Consumption Patterns: Essentially 100% as a uricosuric agent、U.S. Production: (1977) Probably > 4.54 x 10+5 g、(1978) Probably > 4.54 x 10+5 g、Production volumes for non-confidential chemicals reported under the Inventory Update Rule. [Table#4347]、[US EPA、Non-confidential Production Volume Information Submitted by Companies for Chemicals Under the 1986-2002 Inventory Update Rule (IUR). 4H-Pyrazolo、General Manufacturing Information: 4H-Pyrazolo[3、4-d]pyrimidin-4-one、1、5-dihydro-: ACTIVE |
登记用途：Uses: MEDICATION、MEDICATION (Vet):、THERAPEUTIC CATEGORY: Treatment of hyperuricemia and chronic gout、antiurolithic.、Use (kg) in Switzerland (2009): >5000、Use (kg、approx.) in Germany (2009): >100000、Use (kg) in USA (2002): 59900、Use (kg) in France (2004): 54247、Consumption (g per capita) in Switzerland (2009): 0.64、Consumption (g per capita、approx.) in Germany (2009): 1.2、Consumption (g per capita) in the USA (2002): 0.21、Consumption (g per capita) in France (2004): 0.9、Excretion rate: 0.28、Calculated removal (%): 75.1、For the treatment of hyperuricemia associated with primary or secondary gout. Also indicated for the treatment of primary or secondary uric acid nephropathy、with or without the symptoms of gout、as well as chemotherapy-induced hyperuricemia and recurrent renal calculi.、Methods of Manufacturing: Reaction of malononitrile and triethyl orthoformate to form ethoxymethylene malononitrile which is reacted with hydrazine、hydrolyzed、and condensed with formamide.、(Ethoxymethylene)malononitrile is reacted with hydrazine hydrate via deethanolation and addition thus cyclizing to form 3-aminopyrazole-4-carbonitrile. Controlled hydration of nitrile forms the corresponding carboxamide which、on condensation with formamide、yields allopurinol.、Formulations、Preparations: Allopurinol Preparations: (AHFS、2009)、Table: Allopurinol Preparations: (AHFS、2009) [Table#4346]、Oral Tablets、100 mg、Lopurin (scored)、Boots、Zyloprim (with povidone、scored)、Burroughs Wellcome、300 mg、Burroughs Wellcome.、Tablets、100 and 300 mg、Consumption Patterns: Essentially 100% as a uricosuric agent、U.S. Production: (1977) Probably > 4.54 x 10+5 g、(1978) Probably > 4.54 x 10+5 g、Production volumes for non-confidential chemicals reported under the Inventory Update Rule. [Table#4347]、[US EPA、Non-confidential Production Volume Information Submitted by Companies for Chemicals Under the 1986-2002 Inventory Update Rule (IUR). 4H-Pyrazolo、General Manufacturing Information: 4H-Pyrazolo[3、4-d]pyrimidin-4-one、1、5-dihydro-: ACTIVE。
别嘌呤醇 是一种化工化合物，登记 CAS 号为 315-30-0，分子式 C5H4N4O（分子量 136.11）。
登记 CAS 号：315-30-0
其分子式 C5H4N4O 由 5 个碳、4 个氢、4 个氮、1 个氧 组成。
别名/同义词：别嘌呤醇 · Allopurinol · 4-Hydroxypyrazolo[3,4-d]pyrimidine
别嘌呤醇 的 CAS 登记号为 315-30-0。
分子式 C5H4N4O，分子量 136.11。
别名/同义词：别嘌呤醇、Allopurinol、4-Hydroxypyrazolo[3,4-d]pyrimidine。
登记用途：Uses: MEDICATION、MEDICATION (Vet):、THERAPEUTIC CATEGORY: Treatment of hyperuricemia and chronic gout、antiurolithic.、Use (kg) in Switzerland (2009): >5000、Use (kg、approx.) in Germany (2009): >100000、Use (kg) in USA (2002): 59900、Use (kg) in France (2004): 54247、Consumption (g per capita) in Switzerland (2009): 0.64、Consumption (g per capita、approx.) in Germany (2009): 1.2、Consumption (g per capita) in the USA (2002): 0.21、Consumption (g per capita) in France (2004): 0.9、Excretion rate: 0.28、Calculated removal (%): 75.1、For the treatment of hyperuricemia associated with primary or secondary gout. Also indicated for the treatment of primary or secondary uric acid nephropathy、with or without the symptoms of gout、as well as chemotherapy-induced hyperuricemia and recurrent renal calculi.、Methods of Manufacturing: Reaction of malononitrile and triethyl orthoformate to form ethoxymethylene malononitrile which is reacted with hydrazine、hydrolyzed、and condensed with formamide.、(Ethoxymethylene)malononitrile is reacted with hydrazine hydrate via deethanolation and addition thus cyclizing to form 3-aminopyrazole-4-carbonitrile. Controlled hydration of nitrile forms the corresponding carboxamide which、on condensation with formamide、yields allopurinol.、Formulations、Preparations: Allopurinol Preparations: (AHFS、2009)、Table: Allopurinol Preparations: (AHFS、2009) [Table#4346]、Oral Tablets、100 mg、Lopurin (scored)、Boots、Zyloprim (with povidone、scored)、Burroughs Wellcome、300 mg、Burroughs Wellcome.、Tablets、100 and 300 mg、Consumption Patterns: Essentially 100% as a uricosuric agent、U.S. Production: (1977) Probably > 4.54 x 10+5 g、(1978) Probably > 4.54 x 10+5 g、Production volumes for non-confidential chemicals reported under the Inventory Update Rule. [Table#4347]、[US EPA、Non-confidential Production Volume Information Submitted by Companies for Chemicals Under the 1986-2002 Inventory Update Rule (IUR). 4H-Pyrazolo、General Manufacturing Information: 4H-Pyrazolo[3、4-d]pyrimidin-4-one、1、5-dihydro-: ACTIVE。
别嘌呤醇（CAS 315-30-0）的独立参考数据，整理自公开化学数据库。
| CAS Registry Number | 315-30-0 |
|---|---|
| PubChem CID | 135401907 |
| Molecular formula | C5H4N4O |
| IUPAC name | 1,5-dihydropyrazolo[5,4-d]pyrimidin-4-one |
| UNII (FDA) | 63CZ7GJN5I |
| Molecular Weight | 136.11 |
|---|---|
| XLogP3 | -0.7 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 3 |
| Rotatable Bond Count | 0 |
| Exact Mass | 136.03851076 |
| Monoisotopic Mass | 136.03851076 |
| Topological Polar Surface Area | 70.1 |
| Heavy Atom Count | 10 |
| Boiling Point | 250.36 |
|---|---|
| Melting Point | >300 |
| Melting Point | 350 °C |
| Solubility | In water, 569 mg/L at 25 °C |
| Solubility | 5.88e+00 g/L |
| LogP | -1.8 |
| LogP | log Kow = -0.55 |
| LogP | -1 |
| LogP | -0.55 |
| Dissociation Constants | 10.2 (at 25℃) |
allopurinol; 315-30-0; 1H-Pyrazolo[3,4-d]pyrimidin-4-ol; Zyloric; Suspendol; Takanarumin; Allopur; Bloxanth; Uriprim; Xanturat; Urbol; Ketobun-A; Nektrohan; Adenock; Aluline; Dabrosin
| Reported hazard statements | H301 (53.1%), H317 (94.4%) |
|---|
H301 (53.1%): Toxic if swallowed [Danger Acute toxicity, oral]
H317 (94.4%): May cause an allergic skin reaction [Warning Sensitization, Skin]
4-Hydroxypyrazolo[3,4-d]pyrimidine · CAS 315-30-0 · C5H4N4O. UNII 63CZ7GJN5I. Boiling Point: 250.36; Melting Point: >300; Melting Point: 350 °C.
数据来源：PubChem / Wikidata；与随货 COA 不一致时以 COA 为准。
English page: Allopurinol